


# IL COLOSSO DA 700 MILIARDI DI DOLLARI

## Global Sales (US \$BN)

■ 2000 ■ 2001 ■ 2002 ■ 2003 ■ 2004 ■ 2005 ■ 2006 ■ 2007



Source: IMS Helath Market Prognosis (includes IMS Audited and Unaudited markets)  
All information current as of March 28, 2008



Audited Market 2007		Sales		% Growth (Const US\$)
		US\$bn	% Mkt Shr	2007
<b>Worldwide</b>		<b>\$663.5</b>	<b>100%</b>	<b>6.1</b>
1	Lipitor (atorvastatin)	13,5	2	-2,8
2	Plavix (clopidogrel)	7,3	1,1	20,5
3	Nexium (esomeprazole)	7,2	1,1	5,3
4	Seretide/Advair (fluticasone+ salmeterol)	7,1	1,1	9,6
5	Enbrel (etanercept)	5,3	0,8	15,3
6	Zyprexa (olanzapine)	5	0,8	1,9
7	Risperdal (risperidone)	4,9	0,7	4,4
8	Seroquel (quetiapine)	4,6	0,7	16,2
9	Singulair (montelukast sodium)	4,5	0,7	14,7
<b>Total Leading 10 Brands</b>		<b>\$63.9</b>	<b>9.6</b>	<b>5.6</b>

Source: IMS MIDAS®, Dec 2007


All information current as of Feb 26, 2008.

\*Excludes unaudited markets, and Russia, Ukraine and Belarus audited data.

Sales cover direct and indirect pharmaceutical channel pharmaceutical wholesalers and manufacturers. The figures above include prescription and certain over-the-counter data and represent manufacturer prices. Totals may not add due to rounding.


# Nuovi farmaci approvati

Dati FdA 1998 - 2002



**12 farmaci innovativi per anno**

# Source of funding and outcome in pharmaco-economic analyses, clinical trials, and meta-analyses of clinical trials of drug treatments



Lexchin, J. et al. *BMJ* 2003;326:1167-1170



# Conflict of interest?



**“I have never been bought, I cannot be bought. I am an icon, and I have a reputation for honesty and integrity, and let the chips fall where they may.” “It is true that there are people in my situation who could not receive a million-dollar grant and stay objective. But I do.”**



Audited Market 2007	Sales		% Growth (Const US\$)
	US\$bn	% Mkt Shr	2007
<b>Worldwide</b>	<b>\$663.5</b>	<b>100%</b>	<b>6.1</b>
Oncologics	41,4	6,2	16,2
Lipid regulators	33,7	5,1	-6,7
Respiratory agents	28,6	4,3	12,3
Acid pump inhibitors	25,6	3,9	2,8
Antidiabetics	24,1	3,6	10,7
Antipsychotics	20,7	3,1	10,7
Antidepressants	19,7	3	-6,8
Angiotensin II antagonists	19,4	2,9	13,6
Anti-epileptics	15,2	2,3	13,5
Autoimmune agents	13,3	2	20,3
<b>Top 10</b>	<b>241.6</b>	<b>36.4</b>	<b>7.3</b>

All information current as of Feb 26, 2008.

\*Excludes unaudited markets, and Russia, Ukraine and Belarus audited data. Sales cover direct and indirect pharmaceutical channel purchases in U.S. dollars from pharmaceutical wholesalers and manufacturers. The figures above include prescription and certain over-the-counter data and represent manufacturer prices. Totals may not add due to rounding.




Audited Market 2007	Sales		% Growth (Const US\$)	
	US\$bn	% Mkt Shr	2007	CAGR 6-Feb
<b>Worldwide</b>	<b>\$663.5</b>	<b>100%</b>	<b>6.1</b>	<b>7.8</b>
North America	304,5	45,9	4,2	8,7
Europe	206,2	31,1	6,7	6,6
AAA	62,2	9,4	13,1	11,3
Japan	58,5	8,8	4,2	2,8
Latin America	32	4,8	12	13,4
<b>10 Key Markets</b>	<b>529,5</b>	<b>79,8</b>	<b>5,1</b>	<b>7,4</b>

All information current as of Feb 26, 2008.

\*Excludes unaudited markets, and Russia, Ukraine and Belarus audited data.

Sales cover direct and indirect pharmaceutical channel purchases in U.S. dollars from pharmaceutical wholesalers and manufacturers. The figures above include prescription and certain over-the-counter data and represent manufacturer prices. Totals may not add due to rounding.

## Global Sales (US \$BN)



Growth Over Previous year (\$ Constant US\$ Growth)

Source: IMS Helath Market Prognosis (includes IMS Audited and Unaudited markets)  
All information current as of March 28, 2008